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Worldwide obesity has reached pandemic proportions with more than 
1.9 billion adults classed as overweight in 2016, of which 650  million 
were obese.1 Since it is a major modifiable risk factor for so many 
cardiovascular diseases, it is no surprise there has been an exponential 
increase in cases of AF coinciding with the rise in obesity. While there 
were an estimated 8.8 million cases of AF in 2010 in Europe alone, by 
2060, this is estimated to rise to 17.9 million.2 Moreover, obesity is now 
the second biggest attributable risk factor for AF after hypertension. 
Together with overweight, it accounted for 17.9% of all AF cases in the 
Atherosclerosis Risk in Communities (ARIC) study.3 While AF risk appears 
to follow a linear pattern with increase in BMI, the pathophysiological 
basis of the obesity–AF relationship is complex and multifactorial.4 
Indeed, various epidemiological studies have demonstrated an apparent 
paradox with regard to outcomes in AF patients; overweight and mildly 
obese patients with AF appear to have an overall better prognosis in 
terms of all-cause mortality compared with lean patients with AF.5 This is 
consistent with other cardiovascular diseases. 
In this review, we will begin with a detailed discussion of the 
epidemiological links between obesity and AF highlighting 
the benefits and relative limitations of using BMI and other 
anthropometric markers in assessing adiposity (obesity is typically 
defined as BMI >30 kg/m2). We will outline general mechanisms 
contributing to AF and place obesity in this context, focusing on 
the pathophysiological mechanisms that underpin the obesity–AF 
relationship with emphasis on recent insights derived from studies 
on adipose tissue biology. Finally, we discuss novel therapeutic 
targets and the importance of a holistic approach to dealing with 
this burgeoning public health issue.
Epidemiology of the Obesity–AF Relationship
Early associations between AF and obesity were observed in patients 
undergoing cardiac surgery, with high BMI being reported in numerous 
studies as a major risk factor for post-operative AF.6–8 Various studies 
including the Framingham Heart Study and a meta-analysis has indicated 
that a rise in BMI parallels a marked increase in AF risk (Table 1).9,10 
The Women’s Health Study found that for every 1 kg/m2 increase in 
BMI, there was a 4.7% increase in risk of developing AF.4 In a cohort of 
47,589 patients prospectively followed up for a mean of 5.7 years in the 
Danish Diet, Cancer and Health Study, BMI independently correlated 
with increased AF risk regardless of gender.11 In a recently published 
cohort of 67,238 patients derived from a database of healthcare claims 
in the US, obesity was associated with new onset AF independent of 
age, diabetes, hypertension and gender.12 
Notably, BMI has even been associated with progression of AF from 
paroxysmal to persistent in a two large community cohort studies.13,14 
The mean age of patients in the Olmsted County study by Tsang et 
al. was 71, suggesting that this relationship may not necessarily be 
applicable to a younger cohort of patients.13 However, a subsequent 
retrospective Danish registry study of 271,203 women who had 
given birth found that while the overall AF incidence remained low 
in this young population, obesity remained a significant independent 
predictor for AF.15 Indeed, the generalisability of the obesity-induced 
Abstract
Obesity is already a major global public health issue, implicated in a vast array of conditions affecting multiple body systems. It is now 
also firmly established as an independent risk factor in the incidence and progression of AF. The rapidly rising morbidity, mortality and 
healthcare costs associated with AF despite implementation of the three pillars of AF management – anticoagulation, rate control 
and rhythm control – suggest other strategies need to be considered. Compelling data has unveiled novel insights into adipose 
tissue biology and its effect on arrhythmogenesis while secondary prevention strategies targeting obesity as part of a comprehensive 
risk factor management programme have been demonstrated to be highly effective. Here, the authors review the epidemiological basis of 
the obesity–AF relationship, consider its underlying pathophysiology and discuss new therapeutic opportunities on the horizon. 
Keywords
Atrial fibrillation, obesity, obesity paradox, adiposity, epicardial fat, risk factor management
Disclosure: VV’s research is funded jointly by Barts Charity and Abbott Vascular. PL is supported by National Institute for Health Research Biomedical Research Centre at 
University College London Hospitals NHS Foundation Trust and Barts Biomedical Research Centre.
Received: 10 December 2018 Accepted: 28 January 2019 Citation: Arrhythmia & Electrophysiology Review 2019;8(1):28–36. DOI: https://doi.org/10.15420/aer.2018.76.2
Correspondence: Pier Lambiase, UCL Institute of Cardiovascular Science, Gower Street, London, WC1E 6BT, UK. E: p.lambiase@ucl.ac.uk
Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, 
provided the original work is cited correctly.
Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology 
and Novel Therapeutic Opportunities
Vishal Vyas1,2,3 and Pier Lambiase3,4
1. Barts and The London School of Medicine and Dentistry, London, UK; 2. Queen Mary University of London, London, UK;  
3. Barts Heart Centre, St Bartholomew’s Hospital, London, UK; 4. Institute of Cardiovascular Science, University College London, London, UK
Obesity and Atrial Fibrillation
A R R H Y T H M I A  &  E L E C T R O P H Y S I O L O G Y  R E V I E W 29
AF risk remains true across geographical and racial boundaries. 
Berkovitch et al. demonstrated in a large Israeli cohort of 18,290 
men and women that overweight and obesity were associated with a 
higher AF risk and that weight reduction corresponded to a reduced 
risk of developing AF.16 They reported a 7% reduction in AF incidence 
for every 1 kg/m2 drop in BMI. Much of the obesity–AF risk is often 
attributed to other coexisting cardiovascular risk factors given obesity 
is associated with conditions such as diabetes and hypertension. 
A Korean study attempted to account for this by reviewing a cohort 
of so-called metabolically healthy obese (MHO) patients; those with a 
high BMI but who were free of other morbidity.17 They retrospectively 
reviewed nearly 400,000 patients and found the MHO cohort also 
had an increased risk of AF development; on multivariate analysis 
they had a hazard ratio of 1.3 compared with their healthy non-obese 
counterparts. This would suggest that the obesity–AF relationship 
appears to stand beyond conventional risk factors.
The Obesity Paradox and AF
While there is a consistently and extensively reported relationship 
between increasing BMI and AF risk, progression and recurrence, 
a counter-intuitive opposite effect is observed regarding mortality. 
Known as the obesity paradox, overweight (BMI 25–30 kg/m2) and 
mildly obese (BMI 30–35 kg/m2) people appear to have lower all-cause 
mortality in long-term follow-up studies.18–20 Indeed, this phenomenon 
stands true for many cardiovascular diseases.5 A meta-analysis 
pooling nine studies involving 49,364 participants found that 
underweight (BMI <18.5 kg/m2) Asian patients with AF were at 
increased risk of embolic events, such as stroke and systemic 
embolism, as well as cardiovascular and all-cause death.21 Additionally, 
they found that in all AF patients, overweight and obesity were not 
associated with these outcomes. 
In order to dissect the potential reasons for this paradox, it is important 
to consider the characteristics of the patients included in these studies. 
The authors allude to various confounding factors that could account 
for this phenomenon. First, a greater proportion of patients with AF 
in cohort studies tend to be overweight or obese (78% in the Pandey 
study) while those patients who have normal BMI tend to be significantly 
older (in the Sandhu et al. cohort, obese patients were significantly 
younger).18,19 Age is particularly relevant given it is a major predictor of 
all-cause mortality in AF.22 Second, there appears to be a greater use 
of rhythm control strategies and anticoagulation in patients with high 
BMI, potentially to account for a greater proportion of persistent AF in 
groups with a higher BMI.18 Third, patients with high BMI tend to have 
higher blood pressures facilitating greater use of appropriate cardiac 
medications.23 Fourth, patients with an apparently normal BMI may 
have other medical conditions which lead to a relatively catabolic or 
pro-inflammatory state and that increased BMI provides a metabolic 
reserve in this case. Fifth, cardiorespiratory fitness is being increasingly 
recognised as a major factor in reducing AF. 
Table 1: Population Studies Showing an Association of Obesity with AF
Study Country Cohort Details Participant Characteristics AF Outcomes
Huxley et al. 20113 US •  Atherosclerosis Risk in Communities Study
• Prospective cohort
• Mean follow-up 17.1 years
• 14,598 participants
• 55% female
• Mean age 54.2 years
17.9% AF attributed to overweight and 
obesity
Tedrow et al. 20104 US • Women’s Health Study
• Prospective cohort
• Mean follow-up 12.9 years
• 34,309 participants
• 100% female
• Mean age 55 years
4.7% increase in AF per 1 kg/m2 increase 
in BMI
Wang et al. 20049 US •  Framingham Heart and Offspring  
Studies
• Prospective cohort
• Mean follow-up 13.7 years
• 5,282 participants
• 55% female
• Mean age 57 years
4% increase in AF per 1 kg/m2 increase 
in BMI
Frost et al. 200511 Denmark • Danish Diet, Cancer, and Health Study
• Prospective cohort
• Mean follow-up 5.7 years
• 47,589 participants
• 53% female
• Mean age 56 years
Hazard ratio of 1.08 for men and 1.06 for 
women for AF/flutter per  
1 kg/m2 increase in BMI 
Foy et al. 201812 US • Insurance database
• Prospective cohort
• Follow-up 8 years
• 67,278 participants
• 76.9% female
• Mean age 43.8 years
Odds ratio of 1.4 for AF in obese 
participants compared with  
non-obese
Tsang et al. 200813 US •  Olmsted County patients with  
paroxysmal AF
• Prospective cohort
• Median follow-up 5.1 years
• 3,248 participants
• 46% female
• Mean age 71 years
BMI predicted progression of paroxysmal 
to permanent AF with hazard ratio of 
1.04
Sandhu et al. 201414 US • Women’s Health Study
• Prospective cohort
• Median follow-up 16.4 years
• 34,309 participants
• 100% female
• Age ≥45 years
BMI associated with  
non-paroxysmal compared with 
paroxysmal AF with hazard ratio of 1.07
Karasoy et al. 201315 Denmark • Registry of young women giving birth
• Retrospective registry
• Median follow-up 4.6 years
• 271,203 participants
• 100% female
• Mean age 30.6 years
Hazard ratio for AF 1.07 in obese women 
compared with normal weight
Berkovitch et al. 201616 Israel • Tertiary medical centre database
• Prospective cohort
• Mean follow-up 6.4 years
• 18,290 participants 
• 27% female
• Mean age 49 years
Hazard ratio for AF of 2.04 for obese 
compared with normal weight
Lee et al. 201717 South Korea •  Korean National Health Insurance  
database
• Retrospective cohort
• Mean follow-up 7.5 years
• 389,321 participants
• 47.9% female
• Mean age 45.6 years
Hazard ratio of 1.3 for AF in obese 
compared with non-obese
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Qureshi et al. demonstrated in a large multi-racial cohort of 64,561 
adults that for every one metabolic equivalent achieved during 
treadmill testing, there was a 7% lower risk of incident AF even when 
accounting for potential confounders.24 In the CARDIO-FIT study, 
Sanders et al. showed in 308 patients with AF that for every two 
metabolic equivalents gained following their risk factor management 
and tailored exercise programme, there was a twofold improvement 
in arrhythmia-free survival.25 This was accompanied by reduced AF 
burden and an improvement in symptoms. More recently, Malmo et 
al. found that after a 12-week interval training programme for patients 
with paroxysmal AF, AF burden, as measured by implantable loop 
recorders, reduced by 50% compared with controls.26 Additionally, the 
authors observed a trend towards fewer cardioversions and hospital 
admissions alongside significant symptomatic improvements.
The BMI Effect
There are relative pros and cons of using BMI as a measure of adiposity. 
BMI is the most widely used marker of obesity with obvious advantages 
in terms of ease of obtaining height and weight data on patients. 
However, it fails to capture body fat distribution or take into account 
body composition.27,28 For instance, athletes with a high muscle mass 
and a higher weight may fall into an overweight category despite 
having a relatively low body fat composition. On the other hand, 
central abdominal obesity is associated with deleterious outcomes.29 
Various other anthropometric markers, such as waist circumference 
and waist-to-hip ratio, may better indicate the distribution of adiposity 
and better reflect risk. Indeed, lean body mass was recently reported 
in a Danish registry cohort as the predominant anthropometric risk 
factor for AF with other markers not showing an association with 
AF when adjusted for lean body mass.30 In a cohort of 130,473 UK 
Biobank participants without any smoking-related disease or weight 
loss, no significant difference in mortality was seen between normal 
and overweight groups (stratified by BMI).29 However, in each group, 
a higher waist-to-hip ratio reflecting central adiposity was associated 
with excess mortality risk. 
Taken together, there are numerous potential causes that could 
account for this apparent obesity paradox seen with AF and other 
cardiovascular conditions (Figure 1). Furthermore, additional 
unaccounted confounding factors and selection bias, such as a genetic 
predisposition to AF, also need to be considered. Certainly, given the 
improvements observed in AF outcomes with risk factor management 
and weight loss, the apparent obesity paradox should not deter from 
an aggressive risk factor optimisation strategy to manage AF.
The Pathophysiological Context of the  
Obesity–AF Relationship 
Obesity sits alongside a number of conventional cardiovascular risk 
factors that often accompany it and increase AF risk, such as diabetes, 
hypertension, metabolic syndrome and ischaemic heart disease. These 
factors will promote structural atrial remodeling, fibrosis, wave break, 
micro reentry and AF, even in the absence of obesity. Importantly, some 
of the mechanistic pathways that lead to AF in these conditions are 
shared with obesity–AF pathophysiology. For instance, hypertension 
induces haemodynamic changes such as increases in left ventricular 
filling pressures, stiffness and diastolic dysfunction that are also 
seen in obese states.31 Moreover, activation of the renin-angiotensin-
aldosterone system typically observed in hypertensive patients, is 
similarly seen in obesity.32 Adipocytes have been documented to 
directly produce aldosterone, and aldosterone antagonists have been 
noted to be particularly effective in patients with heart failure with 
reduced ejection fraction with associated abdominal obesity.33–35 In 
the case of diabetes, persistent hyperglycaemia is associated with the 
development of advanced glycation end-products which can infiltrate 
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the myocardium provoking fibrosis and hypertrophy, in turn distorting 
the architecture of the heart to make it more conducive to AF genesis.36,37 
While this can be independent of obesity, the fibrotic mediators, such 
as the transforming growth factor beta (TGF-beta) superfamily, are 
common to both pathways.36 Similarly, diastolic dysfunction is common 
in the diabetic heart and is similar to that seen in obesity. 
Factors such as sleep apnoea/obesity hypoventilation syndrome (often 
known together as sleep-related breathing disorders) are emergent 
players to consider. In a study looking at patients being evaluated for 
bariatric surgery, sleep-related breathing disorders were present in 88% 
of patients.38 Moreover, the Sleep Heart Health Study demonstrated 
that patients with sleep-related breathing disorders were at fourfold 
increased risk of AF and threefold increased risk of non-sustained 
ventricular tachycardia following adjustment for several confounders.39 
We will discuss the mechanistic basis for this in the following section.
Obesity-Related Haemodynamic Changes
Obesity is associated with a host of haemodynamic changes that 
alter cardiac structure and physiology to make it more conducive to 
AF development and maintenance. Adiposity is associated with an 
increase in total blood volume with this typically resulting in increased 
cardiac output. With little change in heart rate, the rise in cardiac output 
is predominantly due to an increase in stroke volume. Unfortunately, 
a sustained rise in cardiac output is associated with left ventricular 
enlargement and eccentric or concentric hypertrophy.40 With raised left 
ventricular filling pressures, diastolic dysfunction occurs and over time 
with persistently raised filling pressures and left ventricular hypertrophy, 
systolic impairment may also occur.41 In addition to this, increased BMI 
is associated with left atrial enlargement with raised left atrial pressures 
and volumes.42 A consequent increase in pulmonary capillary pressures 
result. With obesity commonly associated with sleep-related breathing 
disorders, the cycle of repeated hypoxia, acidosis and arousal from 
sleep can alter autonomic tone, increasing the risk of abnormal cardiac 
impulse formation, as well as increasing pulmonary arterial pressures 
which in turn can lead to right ventricular hypertrophy and failure.39 
Left unchecked, biventricular hypertrophy and impairment can result 
with associated distortion in left atrial architecture and haemodynamics 
providing the ideal substrate for AF genesis and persistence. 
Epicardial Fat, Adipose Tissue Biology and AF
Given adipose tissue distribution appears to be a key factor in 
determining cardiovascular risk, it is no surprise that the role of 
distinct adipose tissue depots is of intense interest.43 With more 
sophisticated cross-sectional imaging modalities such as CT and MRI 
being increasingly used for cardiac imaging, the visceral fat layer 
directly overlying the myocardium – epicardial adipose tissue (EAT) – 
can be directly imaged. Of note, pericardial fat is often referred 
to interchangeably with EAT in the literature but strictly speaking 
paracardial fat refers to the layer of fat external to the parietal 
pericardium and pericardial fat is the combination of both EAT and 
paracardial fat.44 
EAT covers 80% of the heart’s surface and up to 20% of the heart’s 
weight, predominantly overlying the coronaries, atrioventricular and 
interventricular grooves but also spanning the atria and ventricles.45,46 
There are no fascial boundaries between EAT and the myocardium 
and they share the same blood supply, the coronary vessels, 
facilitating direct paracrine and vasocrine effects on the heart.47 EAT’s 
physiological roles include thermoregulation, a source of energy and 
mechano-protection.47,48 A seminal post-mortem study assessing 
adiposity of the heart in 1933 showed that 98% of obese patients had 
excessive epicardial fat.49 Cross-sectional imaging data has indicated 
EAT volume correlates with increased AF risk with left atrial EAT 
volume a particular predictor of AF.50–52 Worse outcomes following AF 
ablation and also post-operative AF in the cardiac surgical setting have 
been reported.51,53 A meta-analysis confirming this association between 
EAT and AF has shown an overall odds ratio of 2.61 per each standard 
deviation increase in EAT volume with an even higher odds ratio for 
persistent AF.54
Role of Inflammation 
EAT is a highly active visceral tissue producing a host of different pro- 
and anti-inflammatory adipocytokines, metabolic and growth factors 
that can directly diffuse into the myocardium.45,48 Various lines of 
evidence suggest local inflammation is a key mediator in AF. In a study 
looking at the immune cell profile of patients undergoing valve surgery 
with either no history of AF or those with persistent AF, the number 
of CD45+ cells (a pan-leukocyte marker) was significantly higher in 
the atrial myocardium of AF patients.55 This was corroborated in a 
study by Smorodinova et al. demonstrating that not only were there 
higher CD45+ cell populations in the AF cohort but specifically CD3+ 
T lymphocytes and CD68+ cells (likely corresponding to dendritic cells) 
were significantly higher in the AF cohort.56 In coronary artery bypass 
surgery patients, where AF is a common post-operative complication, 
high levels of pro-inflammatory cytokines including tumour necrosis 
factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and IL-6 were 
observed in the EAT compared with subcutaneous adipose tissue 
samples.57 AF patients undergoing valve surgery were found to have 
higher levels of right atrial nuclear factor-kappa beta (NF-kappa beta), 
which is a key regulator of the immune response. Additionally, TNF-
alpha and IL-6 levels were higher and increased fibrosis and severe 
lympho-monocyte infiltration were seen.58 Clearly, local inflammation 
mediated by a locally driven immune cell and cytokine response 
appears to play a key role in AF pathophysiology and is likely to 
underpin the EAT-AF relationship. 
Fibrosis and Lipotoxicity
Alongside inflammation, fibrosis is recognised as a central factor in 
the development of an arrhythmogenic substrate.41 Pro-inflammatory 
cytokines and growth factors such as activin A and matrix 
metalloproteinases are likely to mediate a fibrotic effect on the atrial 
myocardium via paracrine pathways.59,60 In a study by Venteclef et al, 
only the EAT secretome – and not the subcutaneous secretome – 
applied to an atrial preparation induced myocardial fibrosis with the 
myofibroblasts able to produce extracellular matrix components.59 
This fibrotic effect was attributed to activin A which reproduced the 
significant fibrotic effect when applied to the atrial preparation with 
upregulation of pro-fibrotic genes. The fibrotic effect was negated by 
application of an activin-A antibody.59 Activin-A is a member of the 
TGF-beta superfamily and induced expression of TGF-beta1 and beta2 
in the same study.59 TGF-beta1 has been found to cause selective 
atrial fibrosis and increase vulnerability to AF when overexpressed in 
a transgenic mouse model.60 Fibrosis plays a major role in creating the 
electrical heterogeneity, regions of local conduction block, changes 
in atrial refractoriness and the formation of reentrant circuits that 
ultimately form the substrate for AF.61,62
While inflammation and fibrosis play central roles in the obesity–AF 
cascade, direct fatty infiltration of the myocardium in obesity is also 
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likely to play a role in inducing deleterious structural and electrical 
changes in the atria.63 Mahajan et al. used an ovine model of obesity 
with sheep fed a high-fat diet for a period of 72 weeks.63 Extensive 
imaging and electrophysiological analysis showed that the sheep 
displayed a higher AF burden with enlarged atria and EAT fatty 
infiltration of the posterior left atrial wall. This was accompanied by 
significant atrial fibrosis, reductions in conduction velocity in both 
atrial chambers and reduced posterior left atrial endocardial voltages. 
These insights into adiposity and AF must be put into context of the 
study. It used a laboratory animal model of obesity with sheep fed 
a high calorie and high fat diet that may not necessarily reflect the 
model of obesity seen worldwide, which is caused by Western diet and 
sedentary lifestyle. The authors acknowledge that it is not possible to 
draw a causal link between fatty infiltration and AF from this study.63 
Direct Electrophysiological Effects of the Secretome
In addition to the inflammatory and fibrotic mediators that may 
underpin the obesity–AF relationship, visceral fat and its secretome 
has been reported to have direct electrophysiological effects in left 
atrial (LA) cardiomyocyte co-culture experiments in rabbits.64 Lin et al. 
demonstrated that epicardial, abdominal and retrosternal adipocytes 
all prolong the LA action potential, while epicardial adipocytes also 
significantly altered the resting membrane potential.64 The late sodium 
current, L-type calcium channel current and transient outward current 
were all increased in the co-cultured cells while delayed rectifier 
potassium currents were smaller.64 The authors also noted greater 
isoprenaline-induced delay after depolarisations in the co-cultured 
cells.64 Taken together, these changes in action potential would all 
promote arrhythmogenicity in left atrial cardiomyocytes and illustrate 
the extensive direct modulatory effects of visceral fat.
Autonomic Nervous System in Obesity
Autonomic dysfunction secondary to obesity with concomitant sleep 
apnoea has been shown to trigger AF in animal models.65 Moreover, 
EAT contains the ganglionated plexi that are thought to be key 
mediators of autonomic modulation of the heart.66 In a canine model 
by Po et al., parasympathomimetics were injected into EAT resulting 
in bradycardia followed by premature depolarisations and subsequent 
spontaneous AF.67 The site of firing was thought to arise from both the 
pulmonary vein and non-pulmonary vein sites. Further evidence of the 
role of ganglionated plexi in AF comes from ablation of the plexi as part 
of AF ablation procedures, which tends to diminish AF inducibility.68 
A recent study looked at a cohort of paroxysmal AF patients undergoing 
coronary artery bypass surgery where botulinum toxin targeting the 
ganglionated plexi was injected into the EAT at the time of operation. 
The investigators found that there was a significant reduction (7% 
versus 30%) in the percentage of patients having postoperative AF 
in the botulinum toxin group at 30 days with a sustained difference 
seen at 1-year follow-up.69,70 The mechanism for this observed effect 
is likely to involve targeting the deleterious role of the autonomic 
nervous system on AF inducibility. Botulinum toxin inhibits the 
exocytic release of acetylcholine from pre-synaptic vesicles affecting 
parasympathetic cholinergic neurotransmission.71 When injected into 
the epicardial fat pads which play host to ganglionated plexi, which 
harbours predominantly parasympathetic neurons, it is likely to cause 
temporary suppression of cholinergic firing. AF vulnerability is linked 
to the duration of the atrial effective refractory period (ERP) and the 
dispersion of the ERP.72 Vagal activation shortens the atrial ERP and 
increases dispersion. A canine study has demonstrated increased ERP 
dispersion and increased AF vulnerability after toxin was injected into 
the epicardial fat pads.72 With regard to the longer-term suppression 
of AF reported in the study, the study authors refer to autonomic 
hyperactivity and AF forming a cycle with autonomic activity triggering 
AF and then AF further enhancing autonomic activity.73 The authors 
allude to ‘breaking this cycle’ thus preventing the atrial remodelling 
associated with prolonged periods of AF and reducing the vulnerability 
to episodes of AF in the longer term.70 
The obesity–AF relationship is complex with multiple insults, such 
as inflammation, fibrosis, lipotoxicity and autonomic dysregulation, 
combined with haemodynamic and mechanical changes forming 
the substrate and trigger for AF. With accompanying obesity-related 
comorbidities such as diabetes, hypertension, sleep-related breathing 
disorders and ischaemic heart disease included in this picture, an 
optimal milieu for AF maintenance is created. Figure 2 summarises 
these mechanisms. 
Management of AF in Obese Patients
Drug Therapy
The effect of obesity on AF risk extends to altering aspects of 
management in AF patients. One of the pillars of AF management is 
anticoagulation to minimise thromboembolic complications associated 
with the condition. In a recent study reviewing warfarin dosing in 
patients stratified by BMI, participants with a high BMI, particularly 
more than 40 kg/m2 had significantly higher warfarin requirements.74 
A higher weekly dose of warfarin may have implications for time 
to discharge if the drug is commenced in hospital or in maintaining 
time in therapeutic range. It would seem that the use of direct oral 
anticoagulants (DOACs) including dabigatran, apixaban, rivaroxaban 
and edoxaban for thromboembolism prophylaxis would address this 
issue. However, there is a paucity of large-scale clinical trial data or 
pharmacokinetic analyses in patients of high BMI with most of the data 
gleaned from subgroup analyses.75 
Guidance from the International Society on Thrombosis and Haemostasis 
suggests avoidance of DOACs in morbidly obese patients (BMI >40 kg/
m2) or with a weight of >120 kg, due to limited clinical data.76 Yet this 
approach would exclude a large number of patients who may benefit 
from DOACs. Indeed, in a study of healthy volunteers with a weight 
of more than 120 kg who were taking rivaroxaban, the differences in 
factor Xa inhibition were 10% lower compared with those of normal 
weight.77 Kaplan et al. recently evaluated obese patients including 
those with a BMI >40 kg/m2 undergoing direct current cardioversion 
(DCCV) for AF or atrial flutter on DOACs and warfarin and found there 
was a very low incidence of stroke with none seen in the BMI >40 kg/
m2 cohort at 30 days.78 While the patient cohort group consisted of 
only 761 patients, this study would suggest DOACs appear to be safe 
in a cohort who have a relatively elevated risk for stroke in the first 
month post-DCCV.
AF Procedures
A second pillar of AF management is rhythm control, with one of the 
most commonly performed procedures for patients in AF being DCCV. 
This facilitates prompt evaluation of symptomatology and, in the longer 
term, the assessment of changes in cardiac dimensions and function 
when in sinus rhythm. In turn, this should guide ongoing management. 
Patients with a higher body weight have been found to have a lower 
success rate with cardioversion.79 This is likely to be due to a lower 
energy being delivered to the heart in patients with a higher body 
Obesity and Atrial Fibrillation
A R R H Y T H M I A  &  E L E C T R O P H Y S I O L O G Y  R E V I E W 33
weight with higher energies in a subsequent study being associated 
with a greater likelihood of successful cardioversion in obese patients.80 
Higher energies would achieve increased local atrial current densities 
to depolarise both atria simultaneously and re-establish sinus rhythm. 
A recent randomised study sought to identify additional strategies 
alongside higher energy delivery that would enhance the success rate 
of the procedure.80 The authors found that the use of paddles (rather 
than adhesive patches), manual pressure applied by two operators 
with a gloved hand when patches are used, as well as escalation 
of energies up to 360 J, would enhance the likelihood of successful 
cardioversion in obese patients.
Catheter ablation is a principal rhythm control tool with various 
studies demonstrating that a higher BMI corresponds to a higher AF 
recurrence risk.81–84 While complication rates generally do not differ 
in the studies, greater radiation exposure was noted in one study.83 
Winkle et al. noted that minor complications were significantly higher 
in the morbidly obese group (BMI >40 kg/m2), although no differences 
in major complications were observed.81 The authors allude to the role 
of weight loss strategies to optimise the success of AF ablation. 
Novel Therapeutic Opportunities 
Epicardial Adipose Tissue Biology
Having extensively reviewed the critical local role of EAT in mediating 
the obesity–AF relationship, it is no surprise that it is an emerging 
therapeutic target. Arresting the inflammatory cascade in EAT by 
targeting specific adipocytokines using antibody approaches would 
help to reduce this major component of AF genesis and maintenance. 
Similarly, antibodies to pro-fibrotic agents such as TGF-beta, ideally 
targeted to the adipose tissue for instance with nanoparticle technology, 
would help to improve selectivity of delivery and minimise off-target 
effects, improving safety.85 
Agents that reduce EAT volume have also been investigated. In a 
cohort of patients with diabetes, Iacobellis et al. demonstrated a near 
40% reduction in EAT (as measured by echocardiography) in the group 
given liraglutide, a glucagon-like peptide 1 (GLP-1) agonist in addition to 
metformin.86 There was no double-blinding or reporting of cardiovascular 
outcomes but liraglutide and GLP-1 analogues could be a new area of 
therapeutic investigation. Indeed, GLP-1 receptors are present in adipose 
tissue and appear to regulate adipogenesis providing some mechanistic 
explanation of the phenomenon observed.87 The sodium-glucose 
co-transporter 2 inhibitor dapaglifozin has been shown to produce loss 
in body weight and concomitant reduction in EAT volumes as well as 
reduction in systemic TNF-alpha levels.88 Moreover, dapiglifozin-treated 
EAT explants demonstrated lower levels of chemokines compared with 
untreated explants.89 Further work to assess AF outcomes in patients 
with diabetes treated with these agents would help guide the use of 
these medications in reducing AF risk among this group. 
Role of Imaging
EAT has been shown to be an independent risk factor in AF incidence 
and progression across a range of different settings. Cross-sectional 
imaging approaches such as CT and MRI may help to form novel 
algorithms to predict AF risk and progression. This would be particularly 
relevant to AF ablation. Standards and guidelines with regards to cut-
off EAT volumes to predict AF risk would need to be well-validated 
in large cohorts for them to have widespread clinical utility. One 
study looking at 283 patients with AF looked at echocardiography-
derived EAT thicknesses and suggested using cut-off EAT thicknesses 
values of 6 mm for paroxysmal AF and 6.9 mm for persistent AF.90 
While echocardiography is widely available and inexpensive, there 
are significant limitations with regards to reproducibility and lack 
of volumetric data. Moreover, quantification of EAT sub-depots, for 
instance around the left atrium, is not possible. Antonopoulos et al. 
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used adipose tissue CT attenuation to create the fat attenuation index, 
a new metric to study adipose tissue.91 The fat attenuation index reflects 
the degree of adipocyte differentiation and lipid accumulation in fat 
depots.91 The metric correlates well with coronary inflammation, reliably 
separating stable and unstable lesions in acute coronary syndromes.91 
In the case of AF, a similar technique may help to identify EAT that is 
particularly inflamed and hence more likely to be pathogenic.
Risk Factor Management
Sanders et al. have extensively contributed to the evidence base for 
a comprehensive risk factor management approach to AF.92–6 This 
approach is akin to the secondary prevention approach used for 
patients with ischaemic heart disease. There have been trials that 
look at the role of weight loss alongside risk factor optimization, 
such as good diabetic control, achieving hypertension targets, lipid-
lowering strategies, smoking cessation and alcohol reduction, as well as 
improving cardio-respiratory fitness.25,92–6 This has produced significant 
benefits in reducing the burden of AF. Moreover, reverse cardiac 
remodelling and even a regression from persistent to paroxysmal or no 
AF has been demonstrated.92,95 Notably, a dose-dependent relationship 
between weight loss and freedom from AF was observed.93 The value 
of a physician-led service was highlighted, given 84% patients who 
achieved >10% weight loss were in the physician-led clinic.93 The cost-
effectiveness of such intense risk factor management was evaluated 
by the same group who found that with less medication needed, 
fewer hospitalisations, emergency attendances and procedures, the 
cost-saving benefit amounted to US$12,094. This corresponded to an 
increase of 0.193 quality-adjusted life years.96 
Dietary intervention and bariatric surgery are other avenues to facilitate 
weight loss. Data remains largely speculative with regard to dietary 
approaches to reducing AF risk while bariatric surgery can achieve 
significant sustained weight loss and concomitant large reductions 
in AF risk.97 In the Swedish Obese Subjects cohort study following-up 
2,000 patients undergoing bariatric surgery, a 29% reduction in AF 
risk compared with controls was observed at follow-up of 19 years.98 
Differences in AF rates were only seen between the groups after 
5 years, highlighting the importance of sustained weight loss and the 
temporal delay in altering the AF substrate. 
Primary prevention of AF in the obese at-risk cohort would be the next 
step in helping to control the obesity–AF epidemic. For instance, a 
combination of imaging to calculated threshold volumes of visceral fat 
(such as EAT) to guide risk stratification and using drugs such as GLP-1 
analogues and sodium-glucose co-transporter 2 inhibitors in people 
with diabetes and obesity. 
Conclusion
The seemingly inexorable rise of AF cases worldwide is paralleled by the 
obesity epidemic. Their associated morbidity and mortality combined 
with huge financial costs mark out the obesity–AF relationship as 
one of global health importance. The epidemiological associations 
suggest that obesity increases the risk of AF incidence, progression 
and recurrence. The numerous pathophysiological mechanisms 
highlight the complexity of the relationship but also illustrate the 
potential for new therapeutic opportunities such as targeting the 
inflammatory-fibrotic cascade. Moreover, a comprehensive risk factor 
management approach appears to be a realistic, cost-effective and 
efficacious solution to addressing this problem. Long-term studies 
will confirm whether such strategies yield improvements in hard 
outcomes such as mortality. 
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• Obesity is a key driver in the exponential rise of AF cases 
worldwide.
• High BMI is a major predictor of AF incidence and progression.
• Epicardial adipose tissue (EAT) is the visceral fat layer directly 
surrounding the myocardium and it plays a critical role in 
obesity–AF pathophysiology. EAT’s secretome of inflammatory 
mediators and pro-fibrotic molecules contribute to the 
substrate of AF, and EAT harbours the ganglionated plexi that 
can trigger AF.
• Cross-sectional imaging of visceral fat together with antibody-
based therapeutic agents targeting the inflammatory-fibrotic 
cascade may prove to be novel tools in AF management. 
• A comprehensive risk factor management programme is both 
a clinically and cost-effective strategy to manage AF. 
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